title: Response to letter regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
authors.affiliation: Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
authors.forename: Neal Matsumori
authors.initials: NM
authors.lastname: Rao
authors.affiliation: Department of Neurology, State University of New York (SUNY), College of Medicine, Downstate Medical Center, Brooklyn, NY.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Levine
authors.affiliation: Department of Neurology David Geffen School of Medicine at UCLA, Los Angeles, CA.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Saver
mesh_terms: D002543:Cerebral Hemorrhage / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D020521:Stroke / Q000175:diagnosis* / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods* / Q000592:standards*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D010959:Tissue Plasminogen Activator